BERLEX PREPARING FOR GADOLINIUM DPTA INTRODUCTION IN U.S
BERLEX PREPARING FOR GADOLINIUM DPTA INTRODUCTION IN U.S. under a joint venture arrangement with Immunogenetics. An NDA for the first magnetic imaging contrast agent for head and neck lesions is currently pending at FDA. The product was noted in a Sept. 3 press release by ImmunoGenetics Inc. (IGI) announcing the joint venture agreement with Berlex. "The agreement provides Berlex with exclusive worldwide rights to OB/GYN and diagnostic imaging applications, enabling the entire worldwide organization of Berlex' parent company [West German firm Schering AG] to avail itself of the IGI liposome technology," IGI stated. The announcement marks the third joint venture for IGI. Last month, the company signed an agreement with Rorer covering a long-acting, liposome formulation of the OTC antacid product Maalox ("The Pink Sheet" Aug. 17, T&G-1). Earlier, IGI completed a deal with U.K.-based Coopers Animal Health. The most recent agreement involves two majority-owned IGI subsidiaries, Molecular Packaging Systems (MPS) and Microvesicular Systems, which developed the firm's Micro-Pak liposome encapsulation technology. "Berlex will shortly be introducing the first magnetic resonance imaging contrast agent which may be a likely candidate for the IGI liposome technology," the release states. Primarily a manufacturer and marketer of animal health care products, Vineland, New Jersey-based IGI earned $720,435 in 1986 on sales of $18.4 mil. Through MPS, the company has developed a technology for the liposomal encapsulation of pharmaceuticals, specialty chemicals, proteins, viruses and biological agents such as interferon, insulin and hemoglobin. In March 1987, IGI filed a patent on its liposome process.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth